|Bid||1.6600 x 2200|
|Ask||1.6600 x 2900|
|Day's Range||1.5500 - 1.7000|
|52 Week Range||0.1850 - 4.4700|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorumSAN FRANSICO, CA / ACCESSWIRE / June 11, 2021 / Jaguar Health, Inc. (Nasdaq:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a second time due to a lack of quorum.
SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 27, 2021, the Company granted nonstatutory stock options for the purchase of up to 225,000 shares of the Company's common stock to a new employee, as an inducement award under the Company's 2020 Inducement Plan.
Registration link for webcast appears belowSAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.
Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPACNapo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failureInnovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC founding sponsor Josh Mailman to take place Thursday, June 3rd at 8:30 AM EasternRegistration link for webcast appears belowEquita Group S.
, named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EUEquita Group S., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co.
SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2021 / Napo Pharmaceuticals Inc., the wholly-owned subsidiary of Jaguar Health, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc.
Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of product, the impact of competitive products and pricing, industry trends and product and technology initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. While management believes that its assumptions, expectations, and projections are reasonable in view of current available information, you are cautioned not to place undue reliance on these forward-looking statements.
Newly created Jaguar Health Community Instagram page introduces jaguar-themed contestSAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and the Company's growing community of followers.
Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapyCanalevia will be available by fourth quarter 2021, if conditionally approvedSAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the development program for the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs.
Full Time Employees: 34
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.